Adaptive Biotechnologies Analyst Ratings
Adaptive Biotechnologies Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/24/2023 | 129.89% | Morgan Stanley | $13 → $10 | Maintains | Equal-Weight |
| 10/16/2023 | 198.85% | Piper Sandler | $14 → $13 | Maintains | Overweight |
| 08/08/2023 | 221.84% | Piper Sandler | $15 → $14 | Maintains | Overweight |
| 08/04/2023 | 198.85% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 05/05/2023 | 221.84% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 02/16/2023 | 244.83% | Morgan Stanley | $16 → $15 | Maintains | Equal-Weight |
| 02/15/2023 | 60.92% | Credit Suisse | → $7 | Reiterates | → Underperform |
| 01/05/2023 | 244.83% | Scotiabank | → $15 | Initiates Coverage On | → Sector Outperform |
| 12/21/2022 | 221.84% | Piper Sandler | $7.5 → $14 | Upgrades | Neutral → Overweight |
| 11/07/2022 | 267.82% | Morgan Stanley | $17 → $16 | Maintains | Equal-Weight |
| 10/26/2022 | 72.41% | Piper Sandler | $12 → $7.5 | Maintains | Neutral |
| 08/25/2022 | 83.91% | Credit Suisse | → $8 | Initiates Coverage On | → Underperform |
| 08/17/2022 | 175.86% | Piper Sandler | $7.5 → $12 | Maintains | Neutral |
| 06/03/2022 | 72.41% | Piper Sandler | → $7.5 | Initiates Coverage On | → Neutral |
| 05/24/2022 | 129.89% | Goldman Sachs | $14 → $10 | Maintains | Neutral |
| 05/06/2022 | 313.79% | Morgan Stanley | $27 → $18 | Maintains | Equal-Weight |
| 02/16/2022 | 589.66% | BTIG | $35 → $30 | Maintains | Buy |
| 02/15/2022 | 520.69% | Morgan Stanley | $46 → $27 | Maintains | Equal-Weight |
| 08/06/2021 | 1095.4% | Goldman Sachs | $59 → $52 | Maintains | Neutral |
| 05/07/2021 | 1164.37% | Morgan Stanley | $60 → $55 | Maintains | Equal-Weight |
| 03/03/2021 | 1348.28% | Goldman Sachs | $74 → $63 | Downgrades | Buy → Neutral |
| 02/26/2021 | 1279.31% | Morgan Stanley | $46 → $60 | Maintains | Equal-Weight |
| 11/11/2020 | 957.47% | Morgan Stanley | $42 → $46 | Maintains | Equal-Weight |
| 09/09/2020 | 865.52% | Morgan Stanley | → $42 | Initiates Coverage On | → Equal-Weight |
| 05/19/2020 | 1049.43% | Guggenheim | $44 → $50 | Maintains | Buy |
| 07/23/2019 | 957.47% | BTIG | → $46 | Initiates Coverage On | → Buy |
| 07/22/2019 | 980.46% | Guggenheim | → $47 | Initiates Coverage On | → Buy |
| 07/22/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | 934.48% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 07/22/2019 | 934.48% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 07/22/2019 | 635.63% | Goldman Sachs | → $32 | Initiates Coverage On | → Neutral |
| 07/22/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月24日 | 129.89% | 摩根士丹利 | $13→$10 | 維護 | 等重 |
| 10/16/2023 | 198.85% | 派珀·桑德勒 | $14→$13 | 維護 | 超重 |
| 2023/08/08 | 221.84% | 派珀·桑德勒 | $15→$14 | 維護 | 超重 |
| 08/04/2023 | 198.85% | 摩根士丹利 | $14→$13 | 維護 | 等重 |
| 05/05/2023 | 221.84% | 摩根士丹利 | $15→$14 | 維護 | 等重 |
| 02/16/2023 | 244.83% | 摩根士丹利 | $16→$15 | 維護 | 等重 |
| 02/15/2023 | 60.92% | 瑞士信貸 | →$7 | 重申 | →表現不佳 |
| 01/05/2023 | 244.83% | 加拿大豐業銀行 | →$15 | 開始承保 | →板塊跑贏大盤 |
| 2022年12月21日 | 221.84% | 派珀·桑德勒 | $7.5→$14 | 升級 | 中性→超重 |
| 11/07/2022 | 267.82% | 摩根士丹利 | $17→$16 | 維護 | 等重 |
| 10/26/2022 | 72.41% | 派珀·桑德勒 | $12→$7.5 | 維護 | 中性 |
| 2022年08月25日 | 83.91% | 瑞士信貸 | →$8 | 開始承保 | →表現不佳 |
| 2022/08/17 | 175.86% | 派珀·桑德勒 | $7.5→$12 | 維護 | 中性 |
| 06/03/2022 | 72.41% | 派珀·桑德勒 | →$7.5 | 開始承保 | →中性 |
| 2022年05月24日 | 129.89% | 高盛 | $14→$10 | 維護 | 中性 |
| 05/06/2022 | 313.79% | 摩根士丹利 | $27→$18 | 維護 | 等重 |
| 02/16/2022 | 589.66% | BTIG | $35→$30 | 維護 | 買 |
| 02/15/2022 | 520.69% | 摩根士丹利 | $46→$27 | 維護 | 等重 |
| 08/06/2021 | 1095.4% | 高盛 | $59→$52 | 維護 | 中性 |
| 05/07/2021 | 1164.37% | 摩根士丹利 | $60→$55 | 維護 | 等重 |
| 03/03/2021 | 1348.28% | 高盛 | $74→$63 | 評級下調 | 購買→中性 |
| 02/26/2021 | 1279.31% | 摩根士丹利 | $46→$60 | 維護 | 等重 |
| 11/11/2020 | 957.47% | 摩根士丹利 | $42→$46 | 維護 | 等重 |
| 09/09/2020 | 865.52% | 摩根士丹利 | →$42 | 開始承保 | →等重 |
| 2020/05/19 | 1049.43% | 古根海姆 | $44→$50 | 維護 | 買 |
| 2019年07月23日 | 957.47% | BTIG | →$46 | 開始承保 | →購買 |
| 2019年07月22日 | 980.46% | 古根海姆 | →$47 | 開始承保 | →購買 |
| 2019年07月22日 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 2019年07月22日 | 934.48% | B of A證券 | →$45 | 開始承保 | →購買 |
| 2019年07月22日 | 934.48% | 摩根大通 | →$45 | 開始承保 | →超重 |
| 2019年07月22日 | 635.63% | 高盛 | →$32 | 開始承保 | →中性 |
| 2019年07月22日 | - | 考恩公司 | 開始承保 | →跑贏大盤 |
What is the target price for Adaptive Biotechnologies (ADPT)?
自適應生物技術(Adpt)的目標價格是多少？
The latest price target for Adaptive Biotechnologies (NASDAQ: ADPT) was reported by Morgan Stanley on October 24, 2023. The analyst firm set a price target for $10.00 expecting ADPT to rise to within 12 months (a possible 129.89% upside). 11 analyst firms have reported ratings in the last year.
自適應生物技術公司(納斯達克代碼：ADPT)的最新目標價是由摩根士丹利於2023年10月24日報道的。這家分析公司將目標價定為10美元，預計adpt將在12個月內上漲(可能上漲129.89%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Adaptive Biotechnologies (ADPT)?
最新的分析師對自適應生物技術的評級是多少？
The latest analyst rating for Adaptive Biotechnologies (NASDAQ: ADPT) was provided by Morgan Stanley, and Adaptive Biotechnologies maintained their equal-weight rating.
納斯達克最新分析師評級(納斯達克代碼：ADPT)由摩根士丹利提供，自適應生物科技維持同等權重評級。
When is the next analyst rating going to be posted or updated for Adaptive Biotechnologies (ADPT)?
自適應生物技術(Adpt)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與自適應生物技術公司的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。自適應生物技術的上一次評級是在2023年10月24日提交的，所以你應該預計下一次評級將在2024年10月24日左右的某個時候公佈。
Is the Analyst Rating Adaptive Biotechnologies (ADPT) correct?
分析師對自適應生物技術公司(ADPT)的評級正確嗎？
While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a maintained with a price target of $13.00 to $10.00. The current price Adaptive Biotechnologies (ADPT) is trading at is $4.35, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的自適應生物技術(ADPT)評級保持不變，目標價在13.00美元至10.00美元之間。自適應生物技術公司(Adpt)目前的股價為4.35美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。